215 related articles for article (PubMed ID: 24175841)
21. Preoperative multimodal strategies for risk assessment of adnexal masses: analysis of 1362 cases in a gynecologic cancer center.
Radosa MP; Camara O; Vorwergk J; Diebolder H; Winzer H; Mothes A; Gajda M; Runnebaum IB
Int J Gynecol Cancer; 2011 Aug; 21(6):1056-62. PubMed ID: 21633301
[TBL] [Abstract][Full Text] [Related]
22. Risk of malignancy index for adnexal masses.
Akdeniz N; Kuyumcuoğlu U; Kale A; Erdemoğlu M; Caca F
Eur J Gynaecol Oncol; 2009; 30(2):178-80. PubMed ID: 19480249
[TBL] [Abstract][Full Text] [Related]
23. Risk of Malignancy Index (RMI) in Evaluation of Adnexal Mass.
Javdekar R; Maitra N
J Obstet Gynaecol India; 2015 Apr; 65(2):117-21. PubMed ID: 25883443
[TBL] [Abstract][Full Text] [Related]
24. Accuracy of IOTA Simple Rules, IOTA ADNEX Model, RMI, and Subjective Assessment for Preoperative Adnexal Mass Evaluation: The Experience of a Tertiary Care Referral Hospital.
Vilendecic Z; Radojevic M; Stefanovic K; Dotlic J; Likic Ladjevic I; Dugalic S; Stefanovic A
Gynecol Obstet Invest; 2023; 88(2):116-122. PubMed ID: 36716716
[TBL] [Abstract][Full Text] [Related]
25. Comparisons of Effectiveness in Differentiating Benign from Malignant Ovarian Masses between Conventional and Modified Risk of Malignancy Index (RMI).
Tantipalakorn C; Tinnangwattana D; Lerthiranwong T; Luewan S; Tongsong T
Int J Environ Res Public Health; 2023 Jan; 20(1):. PubMed ID: 36613208
[TBL] [Abstract][Full Text] [Related]
26. Comparison of risk of malignancy indices; RMI 1-4 in borderline ovarian tumor.
Yenen MC; Alanbay I; Aktürk E; Ercan CM; Coksuer H; Karaşahin E; Ozan H; Dede M
Eur J Gynaecol Oncol; 2012; 33(2):168-73. PubMed ID: 22611957
[TBL] [Abstract][Full Text] [Related]
27. Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index.
Enakpene CA; Omigbodun AO; Goecke TW; Odukogbe AT; Beckmann MW
J Obstet Gynaecol Res; 2009 Feb; 35(1):131-8. PubMed ID: 19215560
[TBL] [Abstract][Full Text] [Related]
28. Sonographic discrimination between benign and malignant adnexal masses in premenopause.
Radosa MP; Vorwergk J; Fitzgerald J; Kaehler C; Schneider U; Camara O; Runnebaum IB; Schleußner E
Ultraschall Med; 2014 Aug; 35(4):339-44. PubMed ID: 23775448
[TBL] [Abstract][Full Text] [Related]
29. Ovarian fibroma/fibrothecoma: retrospective cohort study shows limited value of risk of malignancy index score.
Numanoglu C; Kuru O; Sakinci M; Akbayır O; Ulker V
Aust N Z J Obstet Gynaecol; 2013 Jun; 53(3):287-92. PubMed ID: 23611791
[TBL] [Abstract][Full Text] [Related]
30. Risk of malignancy index validity assessment in premenopausal and postmenopausal women with adnexal tumors.
Terzic M; Dotlic J; Likic I; Brndusic N; Pilic I; Ladjevic N; Maricic S; Arsenovic N; Maricic Z
Taiwan J Obstet Gynecol; 2013 Jun; 52(2):253-7. PubMed ID: 23915860
[TBL] [Abstract][Full Text] [Related]
31. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses.
Morgante G; la Marca A; Ditto A; De Leo V
Br J Obstet Gynaecol; 1999 Jun; 106(6):524-7. PubMed ID: 10426607
[TBL] [Abstract][Full Text] [Related]
32. Performance of the Risk of Malignancy Index for Discriminating Malignant Tumors in Women With Adnexal Masses.
Campos C; Sarian LO; Jales RM; Hartman C; Araújo KG; Pitta D; Yoshida A; Andrade L; Derchain S
J Ultrasound Med; 2016 Jan; 35(1):143-52. PubMed ID: 26657746
[TBL] [Abstract][Full Text] [Related]
33. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy.
Moolthiya W; Yuenyao P
Asian Pac J Cancer Prev; 2009; 10(5):865-8. PubMed ID: 20162854
[TBL] [Abstract][Full Text] [Related]
34. Risk of Ovarian Malignancy Algorithm versus Risk Malignancy Index-I for Preoperative Assessment of Adnexal Masses: A Systematic Review and Meta-Analysis.
Chacón E; Dasí J; Caballero C; Alcázar JL
Gynecol Obstet Invest; 2019; 84(6):591-598. PubMed ID: 31311023
[TBL] [Abstract][Full Text] [Related]
35. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods.
Meys EMJ; Jeelof LS; Achten NMJ; Slangen BFM; Lambrechts S; Kruitwagen RFPM; Van Gorp T
Ultrasound Obstet Gynecol; 2017 Jun; 49(6):784-792. PubMed ID: 27514486
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the Risk of Malignancy Index in daily clinical management of adnexal masses.
van den Akker PA; Aalders AL; Snijders MP; Kluivers KB; Samlal RA; Vollebergh JH; Massuger LF
Gynecol Oncol; 2010 Mar; 116(3):384-8. PubMed ID: 19959215
[TBL] [Abstract][Full Text] [Related]
37. Evaluating the risk of malignancy in adnexal masses: validation of O-RADS and comparison with ADNEX model, SA, and RMI.
Wang R; Yang Z
Ginekol Pol; 2023; 94(10):799-806. PubMed ID: 36929789
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses.
Tingulstad S; Hagen B; Skjeldestad FE; Onsrud M; Kiserud T; Halvorsen T; Nustad K
Br J Obstet Gynaecol; 1996 Aug; 103(8):826-31. PubMed ID: 8760716
[TBL] [Abstract][Full Text] [Related]
39. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass.
Al Musalhi K; Al Kindi M; Al Aisary F; Ramadhan F; Al Rawahi T; Al Hatali K; Mula-Abed WA
Oman Med J; 2016 Sep; 31(5):336-44. PubMed ID: 27602187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
